Q-omics provides the consensus-scored B3GNTL1 profile across patient tissues and cancer cell-line models. B3GNTL1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, B3GNTL1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, B3GNTL1 RNA expression shows 18,345 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where B3GNTL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for B3GNTL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes B3GNTL1 survival associations across molecular data types. B3GNTL1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible B3GNTL1 RNA expression–survival associations across cancer types. High B3GNTL1 expression shows unfavorable associations in KIRC, LIHC, UVM, UCS and STAD, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for B3GNTL1 RNA expression.
This table summarizes B3GNTL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for B3GNTL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. B3GNTL1 shows higher tumor expression in KIRC, COAD, KIRP, STAD, LIHC and LUAD. The KIRC box plot shows higher B3GNTL1 RNA expression in tumor versus normal tissue (log2 FC = +0.656, t-test p < 0.001).
This table shows molecular features associated with B3GNTL1 in patient tissues and cancer cell lines. In patient samples, B3GNTL1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, B3GNTL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
